Recruitment Temporarily Suspended into C.E.R.A. Phase II Oncology Trial
Roche announced today that it is temporarily suspending recruitment into its Phase II dose-finding study (NH19960) with the investigational drug C.E.R.A. in anaemic patients with advanced non small cell lung cancer receiving chemotherapy.
This entry was posted on Saturday, February 24th, 2007 at 3:23 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.